Unique ID issued by UMIN | UMIN000029348 |
---|---|
Receipt number | R000031896 |
Scientific Title | A study of efficacy and safety of landiolol hydrochloride for pulmonary resection |
Date of disclosure of the study information | 2017/10/01 |
Last modified on | 2018/10/29 11:15:04 |
A study of efficacy and safety of landiolol hydrochloride for pulmonary resection
A study of landiolol hydrochloride for pulmonary resection
A study of efficacy and safety of landiolol hydrochloride for pulmonary resection
A study of landiolol hydrochloride for pulmonary resection
Japan |
patients who underwent pulmonary resection
Chest surgery | Anesthesiology | Operative medicine |
Malignancy
NO
To investigate the outcome of patients who underwent pulmonary resection with/without landiolol hydrochloride
Safety,Efficacy
Exploratory
Explanatory
Not applicable
2-year relapse free survival rate
Relapse free survival, overall survival
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Medicine |
landiolol hydrochloride
placebo
Not applicable |
85 | years-old | > |
Male and Female
1. male and female under 85
2. ASA 1-2
3. patients who underwent pulmonary resection due to lung cancer
1. supraventricular arrhythmia including atrial fibrillation or atrial flutter
2. patients with sick sinus syndrome including patients with pacemaker implantation
3. patients with severe heart failure (Class III or higher NYHA cardiac function classification)
4. patients with second or higher degree atrioventricular block
5. moderate to severe valve disease
6. patients who have experienced acute cardiovascular events, cerebrovascular events, infectious inflammation within the past 60 days
7. patients with tendency of bradycardia (resting heart rate under 55 times/min)
8. patients with systolic blood pressure less than 80 mmHg
9. patients who had been administered beta blockers before surgery
10. patients with severe bronchial asthma
11. patients who had typical honeycomb lung due to obstructive pulmonary disease (COPD stage 2 or higher) or diffuse lung disease (IP)
12. patients whose cause of atrial fibrillation was identified as electrolyte abnormality, WPW syndrome or hyperthyroidism and so on
13. patients who had been administered antiarrhythmic drugs except for digitalis before pulmonary surgery
14. patients in whom beta-blockers are contraindicated
15. chronic inflammatory diseases
16. patients with severe hepatic impairment
17. patients with severe renal impairment
18. others, patients who are judged inappropriate for this study by principle investigator
64
1st name | |
Middle name | |
Last name | Atsuhiro Sakamoto |
Nippon Medical School
Department of Anesthesiology
1-1-5, Sendagi, Bunkyo-ku, Tokyo
03-3822-2131
no1-saka@nms.ac.jp
1st name | |
Middle name | |
Last name | Tomohiro Harada |
Ono Pharmaceutical Co., Ltd.
Clinical Development Planning 2
8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka-shi
06-6263-3902
t.harada@ono.co.jp
Nippon Medical School Hospital
Ono Pharmaceutical co.,ltd
Profit organization
NO
2017 | Year | 10 | Month | 01 | Day |
Unpublished
Completed
2017 | Year | 01 | Month | 20 | Day |
2017 | Year | 01 | Month | 20 | Day |
2017 | Year | 09 | Month | 29 | Day |
2018 | Year | 10 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031896
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |